de la Iglesia Núria, Konopka Genevieve, Puram Sidharth V, Chan Jennifer A, Bachoo Robert M, You Mingjian J, Levy David E, Depinho Ronald A, Bonni Azad
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Genes Dev. 2008 Feb 15;22(4):449-62. doi: 10.1101/gad.1606508. Epub 2008 Feb 7.
Activation of the transcription factor STAT3 is thought to potently promote oncogenesis in a variety of tissues, leading to intense efforts to develop STAT3 inhibitors for many tumors, including the highly malignant brain tumor glioblastoma. However, the function of STAT3 in glioblastoma pathogenesis has remained unknown. Here, we report that STAT3 plays a pro-oncogenic or tumor-suppressive role depending on the mutational profile of the tumor. Deficiency of the tumor suppressor PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Specifically, we forge a direct link between the PTEN-Akt-FOXO axis and the leukemia inhibitory factor receptor beta (LIFRbeta)-STAT3 signaling pathway. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockout of the STAT3 gene. Remarkably, in contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a complex with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby mediates EGFRvIII-induced glial transformation. These findings indicate that STAT3 plays opposing roles in glial transformation depending on the genetic background of the tumor, providing the rationale for tailored therapeutic intervention in glioblastoma.
转录因子STAT3的激活被认为在多种组织中有力地促进肿瘤发生,这促使人们为包括高度恶性的脑肿瘤胶质母细胞瘤在内的许多肿瘤开发STAT3抑制剂付出了巨大努力。然而,STAT3在胶质母细胞瘤发病机制中的作用仍不清楚。在此,我们报告STAT3根据肿瘤的突变谱发挥促癌或抑癌作用。肿瘤抑制因子PTEN的缺失引发了一系列反应,抑制了小鼠星形胶质细胞和人胶质母细胞瘤肿瘤中的STAT3信号传导。具体而言,我们建立了PTEN-Akt-FOXO轴与白血病抑制因子受体β(LIFRβ)-STAT3信号通路之间的直接联系。因此,PTEN基因敲低在敲除STAT3基因后诱导星形胶质细胞高效恶性转化。值得注意的是,与STAT3在PTEN通路中的抑癌功能相反,STAT3在细胞核中与癌蛋白表皮生长因子受体III型变体(EGFRvIII)形成复合物,从而介导EGFRvIII诱导的胶质细胞转化。这些发现表明,STAT3根据肿瘤的遗传背景在胶质细胞转化中发挥相反的作用,为胶质母细胞瘤的个性化治疗干预提供了理论依据。